Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data

Group 1 - Evaxion (NASDAQ:EVAX) is identified as a promising investment opportunity with significant upside potential, highlighted by an increase in price target from $6 to $11 by Lake Street analyst Thomas Flaten, who maintains a Buy rating on the shares [1][2] - The recent announcement of two-year Phase 2 data for Evaxion's personalized cancer vaccine, EVX-01, in advanced melanoma has contributed to this positive sentiment, indicating the vaccine's potential in treating multiple advanced solid cancers [2] - EVX-01 is recognized as Evaxion's lead clinical asset, and the positive data not only supports the efficacy of the vaccine but also validates Evaxion's overall platform, especially in light of Merck & Co. Inc.'s option exercise for EVX-B3 [2][3] Group 2 - Evaxion is a clinical-stage biotech company focused on developing AI-powered immunology vaccines, previously known as Evaxion Biotech until its name change in May 2025 [3] - Merck & Co. Inc. is a key player in the healthcare sector, providing a range of products including human health pharmaceuticals, veterinary pharmaceuticals, and vaccines [3]